



COPY OF PAPERS
ORIGINALLY FILED

#8
R
8-26-02

Attorney Docket No.: 5565.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Woldike et al.

Application No.: 10/044,426

Group Art Unit: 1636

Filed: November 13, 2001

Examiner: Maria Marvich

Confirmation No: 3262

For: Method For The Production Of FVII

RECEIVED
AUG 14 2002
TECH CENTER 1600/2900

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents
Washington, DC 20231

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on July 24, 2000, Reel 011017, Frame 0887).

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,329,176 B1, issued December 11, 2001, is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,329,176 B1, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,329,176 B1, in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally


disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$110.00, to Novo Nordisk of North America, Inc. Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447.

Date: August 1, 2002

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

COPY OF PAPERS
ORIGINALLY FILED
